Insulet Corporation $PODD Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 14.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 286,104 shares of the medical instruments supplier’s stock after selling 48,322 shares during the period. Allianz Asset Management GmbH’s holdings in Insulet were worth $81,322,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Glenmede Investment Management LP lifted its holdings in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the last quarter. Curi Capital LLC lifted its stake in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares in the last quarter. WINTON GROUP Ltd lifted its stake in Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 37 shares in the last quarter. Camarda Financial Advisors LLC lifted its stake in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Insulet Trading Down 5.6%

NASDAQ:PODD opened at $150.71 on Thursday. The stock’s 50 day moving average price is $172.28 and its 200 day moving average price is $234.54. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The company has a market capitalization of $10.44 billion, a P/E ratio of 35.05, a P/E/G ratio of 1.26 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the company posted $1.02 earnings per share. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on PODD. William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating for the company. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Wells Fargo & Company reduced their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Leerink Partners reduced their price objective on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Finally, Oppenheimer reduced their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $250.00.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.